Maintain adequate nutrition: Ensure sufficient carbohydrate, protein, and overall caloric intake to support research protocol Assess joint and neurological symptoms: Monitor for swelling, carpal tunnel symptoms, or other adverse effects regularly Periodic biomarker assessment: Re-check glucose, lipids, and metabolic markers at mid-point and end of protocol Plan discontinuation protocol: Gradually reduce dosing over 1-2 weeks at research conclusion rather than abrupt cessation Post-research assessment: Verify that all parameters (glucose, lipids, metrics, symptoms) return to baseline after discontinuation Conclusion IGF-1 LR3 has a generally favourable safety profile when used in research with appropriate doses, duration, and monitoring protocols
And here comes other spoilers against the L-carnitine study: Processed meats generally contain less L-carnitine than does fresh red meat
Metabolism reprogramming induced by 2DG makes the neuroblastoma RAS viral oncogene homolog (NRAS) mutant melanoma cells sensitive to BRAF inhibitor (BRAFi) sorafenib [24]
This is not yet body composition change in the way a scan would capture it
2024:1-12 Effect of coagulation and immune responses in acute myocardail infarction could lead to the development of more targeted therapies
I am not a doctor or medical professionaljust someone on my own GLP-1 journey who created this tool in the hope that others may find it useful
